Increasing hepatic TDAG51 protein level in TDAG51−/− mice reduces SREBP-1c activation as measured by SREBP-1c transcript and it's target genes Scd-1 and FAS. These findings of TDAG51 overexpression resulting in the reduction in SREBP-1 are consistent with a recent report showing that TDAG51 overexpression can inhibit the SREBP-1/angiopoietin-like 8 pathway which led to significant improvements in glucose, insulin, and lipid metabolism in a mouse model of gestational diabetes mellitus (32). Here, SCD is linked to gestational diabetes.